Aclaris Therapeutics Inc. (NASDAQ:ACRS) price on Friday, August 06, rose 0.95% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $14.90.
A look at the stock’s price movement, the close in the last trading session was $14.76, moving within a range at $14.17 and $15.08. The beta value (5-Year monthly) was 0.65. Turning to its 52-week performance, $30.38 and $1.82 were the 52-week high and 52-week low respectively. Overall, ACRS moved -15.63% over the past month.
Aclaris Therapeutics Inc.’s market cap currently stands at around $924.99 million, with investors looking forward to this quarter’s earnings report slated for Aug 05, 2021 – Aug 09, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.29, which has seen fiscal year 2021 EPS growth forecast to increase to -$1.34 and about -$1.32 for fiscal year 2022. Per the data, EPS growth is expected to be -11.70% for 2021 and 1.50% for the next financial year.
Analysts have a consensus estimate of $1.69 million for the company’s revenue for the quarter, with a low and high estimate of $1.58 million and $1.8 million respectively. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $6.85 million, representing a 5.70% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ACRS is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
ACRS’s current price about -3.43% and -14.97% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.84, while 7-day volatility ratio is 6.41% and 6.25% in the 30-day chart. Further, Aclaris Therapeutics Inc. (ACRS) has a beta value of 0.59, and an average true range (ATR) of 0.93.
In the market, a comparison of Aclaris Therapeutics Inc. (ACRS) and its peers suggest the former has performed considerably stronger. Data shows ACRS’s intraday price has changed 0.95% in last session and 664.10% over the past year. Looking at another peer, we see that Omeros Corporation (OMER) price has dipped -3.48% on the day. However, the stock is 5.38% off its price a year ago. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.17% and 0.41% respectively in the last trading.
If we refocus on Aclaris Therapeutics Inc. (NASDAQ:ACRS), historical trading data shows that trading volumes averaged 0.38 million over the past 10 days and 739.15K over the past 3 months. The company’s latest data on shares outstanding shows there are 50.34 million shares.
The 3.00% of Aclaris Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 80.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.51 million on Jun 14, 2021, giving us a short ratio of 3. The data shows that as of Jun 14, 2021 short interest in Aclaris Therapeutics Inc. (ACRS) stood at 4.24% of shares outstanding, with shares short rising to 1.89 million registered in May 13, 2021. Current price change has pushed the stock 130.29% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ACRS stock continues to rise going into the next quarter.